Van Houte Hans

Chief Financial Officer

1 company

Good

Trades Analyzed

12M Win Rate

61.9%

Avg 3M Return

-13.1%

Avg 12M Return

-6.5%

Van Houte Hans is a Chief Financial Officer at Nurix Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 13 sells.

Estimated insider holdings value: $780K based on current market prices.

Holdings by Company

NRIXApr 30, 2026

Current Shares47.4K

Value$780.2K

Net Activity-182,628

Bought: 0Sold: 182.6K

Showing 10 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Apr 30, 2026	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	2,388	$16.65	$39,748.98	-4.4%	-	-
Jan 30, 2026	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	3,661	$16.60	$60,766.50	-3.9%	+1.1%	-
Nov 3, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sell	6,284	$12.56	$78,931.44	-14.3%	+35.4%	-
Oct 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	3,130	$12.80	$40,053.67	-6.7%	+39.8%	-
Aug 1, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sell	5,402	$11.03	$59,597.57	-13.2%	+15.8%	-
Jul 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	4,304	$12.01	$51,695.34	-9.5%	+0.2%	-
May 2, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sell	6,198	$11.33	$70,242.55	-15.5%	-0.1%	-
Apr 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	2,438	$11.50	$28,041.14	-5.8%	+3.1%	-
Mar 3, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sell	5,825	$14.49	$84,387.72	-7.9%	-14.4%	+11.5%
Jan 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Financial Officer	Sale+OE	2,811	$19.85	$55,808.69	-3.4%	-42.4%	-17.5%